Pfizer Inc PFE

$28.47 -0.39 (-1.35%)

Valuation

Market cap
164,497,792,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.47
P/E (forward)
9.49
Profit margin
12.42%
Debt to equity
0.70

Trading

Volume
35,356,500
Avg volume
33,489,727
Day's range
$28.35 – $28.67
Shares out
5,699,854,000
Stochastic %K
4%
Beta
0.31
Analysts
Hold
Price target
$30.56

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

graywolf Nov 18, 3:16 PM
$SLS who is stepping up? $JNJ $MRK $PFE ?
1 replies
Outcomes Nov 18, 2:09 PM
$IBRX $PDSB ......'Turbo-Cancers' PSS KNOWS. SAVE THE CHILDREN. 🙏 $PFE $MRNA https://x.com/Fa21519230/status/2122725355454673401?a=nXJqyvwKR1_AbkwtYdI&s=20
0 replies
Sha_B_Ral Nov 18, 2:04 PM
$SNY $PFE This is not a prediction. It will soon become reality.
0 replies
MrPeanutEsquire Nov 18, 1:56 PM
$PFE Im glad were only down 8% from our beat and raise. Its only like the 12th one in a row
1 replies
MrPeanutEsquire Nov 18, 12:04 PM
$PFE Everyone enjoy your rally today. We will stay hear and hold down the fort at the old bear market.
1 replies
focafoca99 Nov 18, 11:55 AM
$PFE secured a licensing deal with Starna Therapeutics for in-vivo CAR-T autoimmune programs, $330M upfront. https://www.rapidticker.com/news/pfe-pfizer-enters-into-exclusive-licensing-e1e05c
0 replies
Parlandoconme Nov 18, 11:49 AM
$TOMZ more food safety means no more shit burgers $TSN and spoilage. Buy baby buy. This stock getting ready to rocket. easily hitting the $12M mark this year. $PFE ray stop eating ebola sandwiches. can really ruin a suit
0 replies
openclassaction2 Nov 18, 11:26 AM
$PFE pfizer has a $44 million chantix settlement pending approval, per open class actions. suit alleged the drug carried an undisclosed nitrosamine impurity. litigation is another line item now
0 replies